Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets [Table Text Block]

The following table summarizes the carrying amount of our Intangible assets, net (in millions):

	December 31,
	2017		2016
Finite-lived intangible assets	$	14,350	$	8,971
Indefinite-lived intangible assets	2,750		—
Total	$	17,100	$	8,971

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The following table summarizes our finite-lived intangible assets (in millions):

	December 31, 2017						December 31, 2016
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangible asset - sofosbuvir	$	10,720	$	2,855	$	7,865	$	10,720	$	2,156	$	8,564
Intangible asset - axicabtagene ciloleucel (DLBCL)	6,200		72		6,128		—		—		—
Intangible asset - Ranexa	688		566		122		688		467		221
Other	546		311		235		455		269		186
Total	$	18,154	$	3,804	$	14,350	$	11,863	$	2,892	$	8,971

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

As of December 31, 2017, estimated future amortization expense associated with our finite-lived intangible assets is as follows (in millions):

Fiscal Year	Amount
2018	$	1,203
2019	1,088
2020	1,064
2021	1,064
2022	1,064
Thereafter	8,867
Total	$	14,350

Schedule of Goodwill [Table Text Block]

The following table summarizes the changes in the carrying amount of goodwill (in millions):

Balance at December 31, 2016	$	1,172
Goodwill resulting from the acquisition of Kite	2,987
Balance at December 31, 2017	$	4,159